Discovery of a novel broad-spectrum antifungal agent derived from albaconazole

ACS Medicinal Chemistry Letters

Volumn 4, Issue 2, 2013, Pages 288-292

  Guillon, Rémi ^a   Pagniez, Fabrice ^a   Picot, Carine ^a   Hédou, Damien ^b   Tonnerre, Alain ^a   Chosson, Elizabeth ^b   Duflos, Muriel ^a   Besson, Thierry ^b   Logé, Cédric ^a   Le Pape, Patrice ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

antifungal agents; Aspergillus; azoles; Candida; thiazolo 4,5 g quinazolin 8(7H) one; zygomycetes

Indexed keywords

ALBACONAZOLE; ITRACONAZOLE; QUINAZOLINONE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CONTROLLED STUDY; DRUG SYNTHESIS; IN VITRO STUDY; IN VIVO STUDY; INVASIVE CANDIDIASIS; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; ZYGOMYCETES;

EID: 84873947513     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml300429p     Document Type: Article

References (23)

1. Groll, A. H.; Lumb, J. New developments in invasive fungal disease Future Microbiol. 2012, 7, 179-184
2. Kelly, S. L.; Arnoldi, A.; Kelly, D. E. Molecular genetic analysis of azole antifungal mode of action Biochem. Soc. Trans. 1993, 21, 1034-1038
3. Bartroli, J.; Turmo, E.; Alquero, M.; Boncompte, E.; Vericat, M. L.; Conte, L.; Ramis, J.; Merlos, M.; Garcia-Rafanell, J.; Forn, J. New azole antifungals: 3. Synthesis and antifungal activity of 3-substituted-4(3H)- quinazolinones J. Med. Chem. 1998, 41, 1869-1882
4. Bartroli, J.; Merlos, M.; Sisniega, H. Overview of albaconazole Eur. Infect. Dis. 2011, 5, 88-91
5. Türel, Ö. Newer antifungal agents Expert Rev. Anti-Infect. Ther. 2011, 9, 325-338
6. Giraud, F.; Logé, C.; Pagniez, F.; Crépin, D.; Le Pape, P.; Le Borgne, M. Design, synthesis and evaluation of 1-(N -benzylamino)-2-phenyl- 3-(1H -1,2,4-triazol-1-yl)propan-2-ols as antifungals agents Bioorg. Med. Chem. Lett. 2008, 18, 1820-1824
7. Giraud, F.; Guillon, R.; Logé, C.; Pagniez, F.; Picot, C.; Le Borgne, M.; Le Pape, P. Synthesis and structure-activity relationships of 2-phenyl-1-[(pyridinyl- and piperidinylmethyl)amino]-3-(1 H -1,2,4-triazol-1-yl) propan-2-ols as antifungal agents Bioorg. Med. Chem. Lett. 2009, 19, 301-304
8. Guillon, R.; Giraud, F.; Logé, C.; Le Borgne, M.; Picot, C.; Pagniez, F.; Le Pape, P. Design of new antifungal agents: synthesis and evaluation of 1-[(1 H -indol-5-ylmethyl)amino]-2-phenyl-3-(1H -1,2,4-triazol-1-yl)propan-2-ols Bioorg. Med. Chem. Lett. 2009, 19, 5833-5836
9. Guillon, R.; Pagniez, F.; Giraud, F.; Crépin, D.; Picot, C.; Le Borgne, M.; Morio, F.; Duflos, M.; Logé, C.; Le Pape, P. Design, synthesis and in vitro antifungal activity of 1-[(4-substituted benzyl)methyl amino]-2-(2,4-difluorophenyl)-3-(1H -1,2,4-triazol-1-yl)propan-2-ols ChemMedChem 2011, 6, 816-825
10. Guillon, R.; Pagniez, F.; Rambaud, C.; Picot, C.; Duflos, M.; Logé, C.; Le Pape, P. Design, synthesis and biological evaluation of 1-[(biarylmethyl)methylamino]-2-(2,4-difluorophenyl)-3-(1H -1,2,4-triazol-1-yl) propan-2-ols as potent antifungal agents: New insights into structure-activity relationships ChemMedChem 2011, 6, 1806-1815
11. Kundu, S.; Mahindaratne, M.; Quintero, M.; Bao, A.; Negretea, G. One-pot reductive cyclization to antitumor quinazoline precursors Arkivoc 2008, ii, 33-42
12. Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D. H.; Sun, L.; Nelson, J.; McMichael, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A. Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor J. Med. Chem. 1996, 39, 918-928
13. Krolski, M. E.; Renaldo, A. F.; Rudisill, D. E.; Stille, J. K. Palladium-catalyzed coupling of 2-bromoanilines with vinylstannanes. A regiocontrolled synthesis of substituted indoles J. Org. Chem. 1988, 53, 1170-1176
14. Alexandre, F.-R.; Berecibar, A.; Wrigglesworth, R.; Besson, T. Efficient synthesis of thiazoloquinazolinone derivatives Tetrahedron Lett. 2003, 44, 4455-4458
15. Testard, A.; Picot, L.; Lozach, O.; Blairvacq, M.; Meijer, L.; Murillo, L.; Piot, J.-M.; Thiéry, V.; Besson, T. Synthesis and evaluation of the antiproliferative activity of novel thiazoloquinazolinone kinases inhibitors J. Enzyme Inhib. Med. Chem. 2005, 20, 557-568
16. Testard, A.; Logé, C.; Léger, B.; Robert, J.-M.; Lozach, O.; Blairvacq, M.; Meijer, L.; Thiéry, V.; Besson, T. Thiazolo[5,4- f ]quinazolin-9-ones, inhibitors of glycogen synthase kinase-3 Bioorg. Med. Chem. Lett. 2006, 16, 3419-3423
17. Tasaka, A.; Tamura, N.; Matsushita, Y.; Teranishi, K.; Hayashi, R.; Okonogi, K.; Itoh, K. Optically active antifungal azoles. I. Synthesis and antifungal activity of (2 R,3 R)-2-(2,4-difluorophenyl)-3-mercapto-1-(1 H -1,2,4-triazol-1-yl)-2-butanol and its stereoisomers Chem. Pharm. Bull. 1993, 41, 1035-1041
18. Pagniez, F.; Le Pape, P. New fluorometric screening test for possible antifungal drugs J. Mycol. Med. 2001, 11, 73-78
19. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard. CLSI Document M38-A; CLSI: Pennsylvania, 2002.
20. Coste, A.; Selmecki, A.; Forche, A.; Diogo, D.; Bougnoux, M. E.; d'Enfert, C.; Berman, J.; Sanglard, D. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates Eukaryotic Cell 2007, 6, 1889-1904
21. Dunkel, N.; Blass, J.; Rogers, P. D.; Morschhäuser, J. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains Mol. Microbiol. 2008, 69, 827-840
22. Ben-Ami, R.; Lewis, R. E.; Leventakos, K.; Kontoyiannis, D. P. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites Blood 2009, 114, 5393-5399
23. Walsh, T. J.; Anaissie, E. J.; Denning, D. W.; Herbrecht, R.; Kontoyiannis, D. P.; Marr, K. A.; Morrison, V. A.; Segal, B. H.; Steinbach, W. J.; Stevens, D. A.; Burik, J. A.; Wingard, J. R.; Patterson, T. F. Treatment of aspergillosis clinical practice guidelines of the infectious diseases of America Clin. Infect. Dis. 2008, 46, 327-360